From Alchemy to IPO: The Business Of Biotechnology

Robbins-Roth, Cynthia

ISBN 10: 073820482X / ISBN 13: 9780738204826

Published by Basic Books, 2001

About this Item

A fascinating glimpse inside the life-and-death business of biotechnology Num Pages: 272 pages, Illustrations. BIC Classification: HBT; KNDC; TCB. Category: (G) General (US: Trade). Dimension: 229 x 152 x 15. Weight in Grams: 402. . 2001. 1st Edition. paperback. . . . . Books ship from the US and Ireland.

Seller Inventory # V9780738204826

Bibliographic Details

• Title: From Alchemy to IPO: The Business Of Biotechnology
• Publisher: Basic Books
• Publication Date: 2001
• Language: English
• ISBN 10: 073820482X
• ISBN 13: 9780738204826
• Binding: Soft cover
• Condition: New

About this title

Synopsis

It is impossible to dispute the extraordinary impact biotechnology is having on our everyday lives. From Alchemy to IPO presents the dramatic story of the revolutionary and controversial business of inventing new cures and blockbuster drugs and a look at how biotech progress is generating powerful profit opportunities on all tiers of business and investment. Written by a well-known industry insider, From Alchemy to IPO addresses the coming-of-age of biotech products and companies and traces the history of biotechnology from its early inception in the '70s to today's heyday of new solutions and breakthrough treatments. It describes the amazing entrepreneurial trail of product development, novel business models, and critical trials that eventually pave the way to market, and describes advances, such as deciphering the genetic code and gene therapy, that just may lead biotech to a higher realm altogether. This is the first book to accurately record the inner workings of an industry-biotechnology-that's on the verge of living up to its monumental promise to change the world as we know it.

About the Author

Cynthia Robbins-Roth, Ph.D., is the founder of BioVenture Consultants, which provides strategic planning and financial assessment to biotech start-ups, pharmaceutical companies, and venture-capital firms. Her biotech column appears regularly in Forbes magazine, and Forbes ASAP named her one of the top twenty-five biotech all-stars. She lives in San Mateo, California.